Reducing chronic obstructive pulmonary disease hospital readmissions. An official American Thoracic Society workshop report.

Press VG, et al. Ann Am Thorac Soc. 2019;16(2):161-170.

The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models.

Buikema AR, et al. Multidiscip Respir Med. 2018;13:38.

Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice.

Cataldo D, et al. Int J Chron Obstruct Pulmon Dis. 2018;13:2089–2099.

Predicting acute exacerbations in chronic obstructive pulmonary disease.

Samp JC, et al. J Manag Care Spec Pharm. 2018;24(3):265–279.

Claims-based risk model for first severe COPD exacerbation.

Stanford RH, et al. Am J Manag Care. 2018;24(2):e45-e53.

Validation and assessment of the COPD treatment ratio as a predictor of severe exacerbations.

Stanford RH, et al. Chronic Obstr Pulm Dis. 2020;7(1):38-48.

High-deductible health plans and healthcare access, use, and financial strain in those with chronic obstructive pulmonary disease.

Gaffney A, et al. Ann Am Thor Soc. 2020; 17(1):49-56.

Triple versus dual inhaler therapy in moderate‐to‐severe COPD: a systematic review and meta‐analysis of randomized controlled trials.

Zayed Y, et al. Clin Respir J. 2019;13(7):413-428.

Once-daily single-inhaler triple versus dual therapy in patients with COPD.

Lipson DA, et al. N Engl J Med. 2018; 378(18):1671-1680.

Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicenter, phase 3 randomised controlled trial.

Ferguson GT, et al. Lancet Respir Med. 2018; 6(10):747-758.

Bringing stability to the chronic obstructive pulmonary disease patient: clinical and pharmacological considerations for frequent exacerbators.

Gulati S, Wells JM. Drugs. 2017;77(6):651–670.

Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease.

Puhan MA, et al. Cochrane Database Syst Rev. 2016;12:CD005305.

Clinical Practice Tools and Resources

The COPD Foundation Pocket Consultant Guide Mobile App

The COPD Pocket Guide, provided by the COPD Foundation, contains comprehensive management information as well as resource tools. It can be downloaded on any mobile device.

Modified Medical Research Council (mMRC) Dyspnea Scale

The mMRC scale, provided by MDCalc, allows for the baseline stratification of dyspnea in COPD, as well as other respiratory diseases, and can be downloaded on any mobile device.

COPD Assessment Test (CAT)

The CAT, provided by the American Academy of Family Physicians, allows assessment of the global impact of COPD (cough, sputum, dyspnea, chest tightness) on patient health status.

COPD Action Plan

The COPD Action Plan, provided by the American Lung Association, is a tool that facilitates the prevention, timely identification, and early and appropriate treatment of COPD exacerbations.

HEDIS Measures and Technical Resources

The National Committee for Quality Assurance’s Healthcare Effectiveness Data and Information Set (HEDIS) is one of health care’s most widely used performance improvement tools.

Patient Resources and Advocacy Organizations

The COPD Foundation Pocket Consultant Guide, Patient-Focused Mobile App

The COPD Pocket Guide for Patients was designed to improve disease management and communication with a patient’s health care team. It includes patient resources such as inhaler and exercise videos as well as tools such as the wallet card and daily symptom tracker that help to collect and share information with the health care team. It can be downloaded on any mobile device.

American Lung Association

The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research.

COPD Foundation

The COPD Foundation’s mission is to prevent and cure COPD and to improve the lives of all people affected by COPD.

Global Initiative for Chronic Obstructive Lung Disease (GOLD)

GOLD partners with health care professionals and public health officials to raise awareness of COPD and to improve prevention and treatment of this lung disease for patients around the world.

National Jewish Health

National Jewish Health integrates the latest scientific discoveries with coordinated care for lung, heart, and immune diseases. Their Patient Education Program provides many free educational opportunities and support groups to assist patients and caregivers with managing illnesses and chronic conditions, such as COPD.